Through this engagement, Daré will provide strategic mentorship, technical guidance, and tailored project management support to Grand Challenges grantee organizations in various geographies worldwide whose pre-clinical research projects are focused on the prevention, diagnosis, and treatment of preeclampsia. Despite its devastating impact—preeclampsia is a leading cause of maternal and infant illness and death globally—there are currently no FDA-approved treatments for this life-threatening condition.
"Preeclampsia remains one of the greatest unmet needs in women's health, with approximately 76,000 moms and 500,000 babies worldwide losing their lives to this condition each year," said Sabrina Martucci Johnson, President and CEO of Daré Bioscience. "This engagement by the foundation will allow us not only to contribute our expertise to advance the work of global innovators, but also to gain invaluable insights into scientific and real-world challenges in this critical area where no approved therapies currently exist."
The multi-year engagement is designed to strengthen the impact, efficiency, and sustainability of research funded through the Gates Foundation's Grand Challenges initiative to reduce the burden of preeclampsia.
"This engagement underscores Daré's mission to improve the health and well-being of women everywhere by supporting the advancement of potential novel solutions for conditions that have been historically overlooked," added Johnson. "Our participation in this foundation initiative is aligned with our long-term strategy to lead in areas of women's health with great need and limited options."
About PreeclampsiaPreeclampsia is a pregnancy complication characterized by high blood pressure and signs of damage to other organ systems, often the liver and kidneys. It typically occurs after 20 weeks of pregnancy in women whose blood pressure had previously been normal. Globally, preeclampsia is a leading cause of maternal and neonatal morbidity and mortality. There are no FDA-approved treatments specifically indicated to prevent or treat preeclampsia.
About Daré Bioscience
Daré Bioscience is a biopharmaceutical company driven by a mission to challenge the status quo, making women's health a priority. Daré believes that innovation does not have to start from scratch. The company's goal is to bring to market as soon as practicable innovative evidence-based solutions that address decades of unmet needs in women's health and enhance outcomes and convenience, primarily in the areas of contraception, sexual health, pelvic pain, fertility, infectious disease, vaginal health and menopause. The potential products Daré identifies, in many cases, already have clinical proof of concept or existing safety data ...
